Tango-Tiger

- China is the first country Who started the invention of the vaccine against COVID-19 And the vaccine is widely used Although the experiment in phase 3 is not yet completed

- China currently has four prototypes of the COVID-19 vaccine approved by the Chinese authorities in an emergency to necessary personnel. And high-risk groups

- A vaccine against COVID-19 from China is a live vaccine. Produced using dead pathogens To stimulate the immune system in the body Without the risk of disease Which is how many vaccines are produced Disease since the original



As companies around the world compete to develop the COVID-19 vaccine, Until many nations have begun approving the use of a vaccine against COVID But news of the COVID-19 vaccine from China, the nation that first encountered the outbreak was May not have been released much yet. In addition to the progress that is being tested in phase 3

About the COVID-19 vaccine from China

So far, there have been four prototypes of vaccines that China have approved for emergency use by necessary personnel. Or various high-risk groups Although clinical testing to prove safety and efficacy has not been completed. The four Chinese COVID-19 vaccines used in a limited range are in phase 3 clinical trials in humans, including the COVID-19 vaccine. Of Sino Farm Company Developed in collaboration with the Wuhan Institute of Biological Products COVID-19 vaccine Of Sino Farm Co., Ltd. developed in collaboration with the Beijing Biological Products Institute Which has already been applied to nearly 1 million Chinese in an emergency. The third phase of experimental data has not been disclosed. COVID-19 vaccine Of the company Cancino Biologics, a subsidiary of the Chinese army That has limited use of the vaccine in the Chinese military and the novel coronavirus Of Sinovac Biotech, which is also used in emergencies Initially, no serious adverse reactions were reported in people receiving the COVID-19 vaccine. In an emergency While the Brazilian Institute of Biomedical Butantan The trial of the Corona Vac vaccine Phase 3 in the country is prepared to reveal the results of the trial in the middle of this month.



Difference between Sinovac vaccines And other national vaccines

Coronavac is an inactivated vaccine that is produced using dead pathogens. To stimulate the immune system in the body without the risk of disease. Which is how many vaccines are produced Disease since the original Meanwhile, the US Camp Moderna and Pfizer vaccines are MRNA vaccines produced from the genetic material of the COVID-19 virus. When injected into the body It will stimulate the immunity of vaccine recipients to produce antibodies that can be used to fight the new coronavirus. This is the first time this vaccine has been used. The strengths of the Coronavac vaccine are Can be stored at the same temperature as a normal refrigerator at 2-8 degrees Celsius. As with the Astraseneca vaccine, with the University of Oxford.

While Moderna's vaccine It must be kept below minus 20 ° C and Pfizer's vaccine must be kept below minus 70 ° C. Oxford will be suitable for developing countries. That does not have the potential to collect large volumes of vaccines at such negative temperatures



Sinovac vaccine efficacy

Although until now it may be difficult to determine the exact efficacy of a Chinese vaccine. As the latest data published in the journal Lancet contains only phase 1 and phase 2 trials, more than 24,000 people are currently enrolled in clinical trials for coronavirus vaccination in Brazil, Turkey and Indonesia. And more trials are expected in Bangladesh and Chile.

Sinovac chose to conduct trials in that country. Due to the strong COVID-19 epidemic, there is a large population And has limited research and development capabilities And even though vaccine trials in Brazil were halted last November, they had to be halted. After the volunteer's death was reported But trials continued after the deaths were not found to be related to vaccines. The exact efficacy of the vaccine can be confirmed only after the trial has been completed.

The ability to produce vaccines from Sinovac

Sinovac is currently able to produce approximately 300 million doses of the vaccine in a year from a new facility in 20,000 square meters.By calculating two vaccine doses per person, it could produce a vaccine for 150 million people. People per year, which accounts for only about 1 in 10 of the Chinese population. The vaccine is now being delivered to Indonesia for distribution to the people of 1 million 2 hundred thousand dosages on December 8, while another 1 million 8 hundred thousand doses will reach Indonesia in January. Sinovac has now entered into contracts for the coronavirus vaccine to countries such as Indonesia, Turkey, Brazil, Chile and negotiations with the Philippines.

The price of the coronavac vaccine remains unclear. But the average price of a vaccine for Chinese medical workers is 1,800 baht, which is still as expensive as Oxford's vaccines. At around 120 baht per dose, while the vaccine from Moderna will be priced at a cost of nearly 1,000 baht. Moderna will be able to produce about 500 million doses of the vaccine next year. AstraZeneca will produce some 700 million doses of the vaccine by the end of the first quarter of next year.

News source:joker123